Methods:Plasma FⅤ:C,FⅦ:C,FⅧ:C,FⅩ:C and FⅪ:C were tested by ALC-2000 fully automatic coagulant-meter in 80patients with malignant tumor(31 lung cancers,21 bowel cancers, 12breast cancers and 16 malignant lymphomas).
Results (1) The mean concentrations of serum ET-1 in normal individuals and in non-tumor patients were (46. 9 ±1 23. 1 ) μg/L and (51. 1 ± 30. 9) μg/L, respectively, while in patients with malignant tumors it was (190. 1 ± 135. 2 - 382. 4 ± 190. 1) μg/L.
Methods The multi-tumor markers protein chip detective system was used to detect the serum levels of 12 tumor markers(CA19-9,CA242,CA125,CA15-3,CEA,AFP,NSE,Free-PSA,PSA,β-HCG,FER and HGH)in 156 malignant tumor patients,98 patients with benign disease and 556 healthy persons.
Methods The serum levels of 12 common tumor markers ,including CA199、NSE、CEA、CA242、CA125、CA153、AFP、Ferritin、free-PSA、PSA、β-HCG and HCH ,were measured with the detective system in 500 malignant tumor patients,150 patients with benign disease and 1 600 healthy examinations .
Detecting 60 malignant tumor patients IL-2,IL-2R and sIL-2R activity after and before He-Ne laser therapy by R3H-TdR incorporation method,enzyme labeling technology and indirect immunofluorescence technology.
Objective: To investigate the frequencies of CD4+ regulatory T(Treg) cells(CD4+CD25+/CD4+CD25high) in peripheral blood of cancer patients,providing the opportunity to determine whether cancer patients exhibit an expanded CD4+CD25high pool.
目的:探讨恶性肿瘤患者外周血CD4+CD25+/CD4+CD25high调节性T细胞(Regulatory T cell,Treg)水平的特点及其临床意义。
Methods: The serum levels of 12 common tumor markers, including CA199, NSE,CEA,CA242,CA125,CA153,AFP,ferrtin,free-PSA,PSA,β-HCG and HGH, were measured with the detective system in 113 digestive tract cancer patients, 48 patients with benign digestive disease and 145 healthy examinations.
The low levels of iron in the serum of patients with malignant tumor may increase colorectal cancer risk.
Pilot study for the evaluation of T-cell-mediated tumor immunotherapy by cytokine gene transfer in patients with malignant tumor
Preoperative chemotherapy was given to most patients with malignant tumor.
All patients with malignant tumor received postoperative chemotherapy.
Destruction of the bone wall was seen in 100% of the patients with malignant tumor of maxilla patients and in 57.8% with the maxillary sinusitis, hence showing a significantly higher incidence in malignant tumors of the maxilla.
Samples of normal tissue (5 cm away from tumor) were also taken from patients with malignant tumors.
No significant change in KPS scores could be observed for those with benign lesions, but 67% of patients with malignant tumors showed a KPS drop ≥30 points.
In the same test positive lymphocyte stimulation against lyophilised fetal cells can be demonstrated in about 50% of a group of patients with malignant tumors.
After stimulation with encephalitogenic protein (EF) sensitized lymphocytes from patients with malignant tumors liberate a factor, which can be demonstrated by the Macrophage-Electrophoretic-Mobility-Test (MEM) (Field and Caspary) .
Serum-sialyltransferase activity was measured in serum samples of 116 patients with malignant tumors of various origins and different clinical stages using asialo-fetuin as the acceptor and cytidine-5'-mono-phospho[14C]sialic acid as the donor.